Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Codexis, Inc. (CDXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Codexis is listed on The Nasdaq Global Select Market, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as reflected in its Form 8-K filings. These filings give investors insight into how Codexis reports its financial condition, strategic actions and material events related to its enzymatic solutions for therapeutics manufacturing and its ECO Synthesis® / ECO Synthesis™ platform.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically contain detailed discussions of Codexis’s business, risk factors, financial statements and management’s analysis of results. For a company focused on enzyme technologies and oligonucleotide manufacturing, these filings can shed light on revenue contributions from its Pharma Biocatalysis business, investments in research and development for platforms such as CodeEvolver® and ECO Synthesis, and the financial impact of collaborations and licensing arrangements.
Codexis also files Form 8-K current reports to disclose material events. For example, an 8-K dated November 6, 2025 reports quarterly financial results and describes a workforce reduction aligned with an enhanced strategic focus on the ECO Synthesis platform, as well as executive leadership changes. Another 8-K dated August 13, 2025 announces financial results for the quarter ended June 30, 2025. These current reports help investors track significant developments between periodic filings.
On this page, users can also review Form 4 insider transaction reports and other relevant filings, where available, to understand equity awards and trading activity by directors and officers. Stock Titan enhances access to these documents with AI-powered summaries that explain key points from lengthy filings, highlight important sections in 10-K and 10-Q reports, and clarify the implications of 8-K disclosures. Real-time updates from EDGAR ensure that new Codexis filings, including those related to its enzyme-based manufacturing initiatives and organizational changes, are reflected promptly for further review and analysis.
Codexis, Inc. ownership update: Opaleye Management Inc., together with Opaleye, L.P. and James Silverman, reports beneficial ownership of 6,785,000 shares of Codexis common stock, representing 7.47% of the class. The filing states this includes 120,000 shares held in separate managed accounts. The filing cites 90,869,349 common shares outstanding as of 03/05/2026 as the basis for the percentage.
Codexis, Inc. is asking stockholders to vote at a virtual annual meeting on June 17, 2026. Investors will elect three Class I directors—Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi—for terms running to the 2029 meeting, ratify KPMG LLP as independent auditor for 2026, and approve, on an advisory basis, executive pay.
Stockholders of record at the close of business on April 20, 2026, when 90,896,567 common shares were outstanding, may vote online, by phone, or by mail. The board is classified into three staggered groups and determined most directors to be independent under Nasdaq rules. The filing also outlines committee structures, director compensation, major shareholders, and audit fees paid to KPMG and former auditor BDO.
Codexis, Inc. Schedule 13G: Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander filed a joint Schedule 13G reporting shared voting and shared dispositive power over 4,734,627 shares of Common Stock (par value $0.0001), equal to 5.2% of the class. The filing lists CUSIP 192005106 and includes a Joint Filing Agreement dated April 13, 2026. The reported holdings are exercised through entities subject to the group’s voting and investment discretion.
Codexis, Inc. reported board changes centered on director departures and reclassification among its staggered board classes. On April 8, 2026, Dennis Wolf resigned from the Board, and from the Audit and Compensation Committees, effective immediately. The company stated his resignation was not due to any disagreement regarding operations, policies or practices.
On April 10, 2026, to rebalance director classes, Esther Martinborough, Ph.D., resigned as a Class II director and was immediately re-elected as a Class III director. She continues on the Board and serves on the Compensation and Strategy Committees and as Chair of the Science & Technology Committee. After this “Class Rebalance,” the Board consists of three Class I, three Class II, and three Class III directors.
Codexis Inc received an amendment to a Schedule 13G/A from The Vanguard Group that reports zero shares beneficially owned in the company. The filing explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries or business divisions to report holdings separately. The filing states that Vanguard and its affiliates hold no more than 5% of the class and that, as reported here, Vanguard beneficial ownership is 0 shares (0%).
Codexis, Inc. reports its 2025 annual results and strategic focus on enzymatic technologies for therapeutics manufacturing. The company recorded a net loss of $44.0 million in 2025 and had an accumulated deficit of $606.8 million as of December 31, 2025.
Codexis is pivoting around its ECO Synthesis enzymatic RNA interference (RNAi) manufacturing platform and its established small-molecule pharma biocatalysis business. The ECO Synthesis Innovation Lab now produces non‑GMP siRNA for preclinical work, with CDMO partnerships evaluating GMP-scale production and a leased GMP facility targeting Phase 1–2 supply by 2027.
In pharma biocatalysis, Codexis supplies enzymes for 18 approved drugs and 15 clinical‑stage drug candidates, while selectively pursuing only higher‑value new projects. Revenue concentration remains high, with one customer contributing about 51% of 2025 revenue. As of March 5, 2026, there were 90,869,349 common shares outstanding.
Codexis, Inc. reported fourth quarter and full-year 2025 results, highlighting higher revenue, a narrowed annual loss and strengthened liquidity. Fourth quarter revenue was $38.9 million, with full-year revenue of $70.4 million, up from $59.3 million in 2024, driven mainly by research and development revenue growth.
The company posted fourth quarter net income of $9.6 million, while the full-year net loss improved to $44.0 million from $65.3 million in 2024. Codexis ended 2025 with $78.2 million in cash, cash equivalents and short-term investments, which it says provides runway through 2027. It also completed a $37.8 million Technology Transfer Agreement with Merck and emphasized progress for its ECO Synthesis and ligase platforms, including multi-gram and kilogram-scale siRNA production for customers.
Codexis, Inc. beneficial owner Laurence W. Lytton reports beneficial ownership of 4,532,069 shares of Common Stock, representing 5.0%.
The percentage is calculated based on 90,324,383 shares outstanding as of November 3, 2025, per the issuer's reported Form 10-Q. The filing is a Schedule 13G disclosure of ownership.
CODEXIS, INC. Chief Scientific Officer Stefan Lutz reported two transactions involving company securities. On February 24, 2026, he sold 5,862 shares of common stock at $1.1329 per share to satisfy tax and other withholding obligations related to vesting Restricted Stock Units, leaving him with 130,421 common shares, which include 23,299 RSUs. On February 23, 2026, he also received a grant of 316,100 stock options with an exercise price of $0.00, vesting 25% on the first anniversary of the grant date and the remaining shares in equal monthly installments over the following three years, subject to his continued employment.